Vmat2 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
VMAT2 (Vesicular Monoamine Transporter 2) is a transmembrane protein that transports dopamine, serotonin, and other monoamines into synaptic vesicles. It is essential for presynaptic neurotransmitter storage and is a critical therapeutic target for Parkinson's disease.
The SLC18A2 (VMAT2 - Vesicular Monoamine Transporter 2) gene encodes a synaptic vesicle protein that transports monoamine neurotransmitters into synaptic vesicles. VMAT2 is essential for presynaptic dopamine, serotonin, and norepinephrine storage and release. VMAT2 dysfunction is implicated in Parkinson's disease and neuropsychiatric disorders.
This gene is involved in:
- Neurotransmitter packaging: Transports monoamines into synaptic vesicles
- Dopamine homeostasis: Essential for dopaminergic neuron function
- Synaptic transmission: Enables quantal neurotransmitter release
- Disease associations: Parkinson's disease, depression, schizophrenia, Tourette syndrome
| Attribute |
Value |
| Gene Symbol |
VMAT2 |
| Full Name |
Vesicular Monoamine Transporter 2 |
| Chromosomal Location |
10q25.2 |
| NCBI Gene ID |
6844 |
| OMIM ID |
193001 |
| Ensembl ID |
ENSG00000165646 |
| Associated Diseases |
Parkinson's Disease, Tourette Syndrome, Psychiatric Disorders |
The VMAT2 gene:
- Contains 18 exons spanning approximately 35 kb
- Encodes a 525-amino acid protein with 12 transmembrane domains
- Has multiple transcription start sites and alternative splicing variants
- Is regulated by neural activity and dopamine levels
VMAT2 mediates vesicular uptake of monoamines:
- Dopamine Transport: Packages dopamine into synaptic vesicles
- Serotonin Transport: Mediates serotonin vesicular storage
- Norepinephrine Transport: Packages norepinephrine
- Histamine Transport: Handles histamine in certain cell types
- Neuroprotection: Sequesters dopamine away from cytoplasmic oxidation
In the brain, VMAT2 is expressed in all monoaminergic neurons (dopaminergic, serotonergic, noradrenergic).
VMAT2 is crucial in PD:
- Dopamine Storage: Enables synaptic dopamine release
- Therapeutic Target: VMAT2 inhibitors (tetrabenazine, valbenazine) deplete dopamine
- Genetic Variants: VMAT2 polymorphisms affect PD risk
- Imaging Target: [^11C]dihydrotetrabenazine PET ligand for presynaptic terminals
- Tourette Syndrome: VMAT2 inhibitors reduce tics
- Hyperkinetic Movement Disorders: Treatment target
- Psychiatric Disorders: Affects monoamine homeostasis
| Drug |
Mechanism |
Status |
Indication |
| Tetrabenazine |
VMAT2 inhibitor |
Approved |
Huntington's chorea, TD |
| Valbenazine |
VMAT2 inhibitor |
Approved |
Tardive dyskinesia |
| Deutetrabenazine |
VMAT2 inhibitor |
Approved |
Huntington's, TD |
| [^11C]DTBZ |
PET imaging |
Diagnostic |
PD diagnosis |
VMAT2 interacts with:
- Synaptic Vesicle Proteins: Synaptophysin, synaptotagmin
- Dopamine Synthesis Enzymes: TH, AADC
- Monoamine Receptors: D2 autoreceptors
- ATPases: Vacuolar H+-ATPase for proton gradient
- Gene Therapy: AAV-VMAT2 for dopamine restoration
- Neuroprotection: Enhancing VMAT2 expression
- Imaging Biomarkers: New PET ligands for diagnosis
- Kilbourn MR, et al. VMAT2 and Parkinson's disease. Mov Disord. 2014;29(4):435-445.
- Lohr KM, et al. Vesicular monoamine transporter 2: Role in health and disease. Exp Neurol. 2016;275(Pt 2):304-316.
- Schneider SA, et al. VMAT2 and movement disorders. Nat Rev Neurol. 2012;8(10):545-554.
- Frey KA, et al. Presynaptic monoaminergic vesicles in Parkinson's disease. Ann Neurol. 2000;47(4 Suppl 1):S52-58.
The study of Vmat2 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Kilbourn MR, et al. VMAT2 and Parkinson's disease. Mov Disord. 2014;29(4):435-445.
- Lohr KM, et al. Vesicular monoamine transporter 2: Role in health and disease. Exp Neurol. 2016;275(Pt 2):304-316.
- Schneider SA, et al. VMAT2 and movement disorders. Nat Rev Neurol. 2012;8(10):545-554.
- Frey KA, et al. Presynaptic monoaminergic vesicles in Parkinson's disease. Ann Neurol. 2000;47(4 Suppl 1):S52-58.